首页>
外文期刊>clinical drug investigation
>Effect of Recombinant or Lymphoblastoid Interferon-agr; on Alanine Aminotransferase in Patients with Chronic Hepatitis C or Chronic Non-A Non-B HepatitisA Meta-Analysis
【24h】
Effect of Recombinant or Lymphoblastoid Interferon-agr; on Alanine Aminotransferase in Patients with Chronic Hepatitis C or Chronic Non-A Non-B HepatitisA Meta-Analysis
展开▼
机译：Effect of Recombinant or Lymphoblastoid Interferon-agr; on Alanine Aminotransferase in Patients with Chronic Hepatitis C or Chronic Non-A Non-B HepatitisA Meta-Analysis
A meta-analysis of published randomised clinical trials was performed to determine the efficacy of recombinant and lymphoblastoid interferon-agr; (IFNagr;) in the induction and maintenance of remission in patients with chronic C or non-A non-B hepatitis. Studies were identified using standard computer techniques for literature searches and by reviewing all references of the papers examined. Each trial evaluated the efficacy of IFNagr; (recombinant and lymphoblastoid)1in comparison with a control group receiving either placebo or no treatment. Since the end-point of the analysis was of a censored-type lsqb;i.e. normalisation of alanine aminotransferase (ALT) levels over timersqb;, a specific method of meta-analysis was employed that allowed the inclusion of trials of different durations and permitted determination of the probability of therapeutic success over time. Two separate meta-analyses were carried out to address (a) the efficacy of IFNagr; during treatment (first meta-analysis) and (b) the relapse risk after drug discontinuation (second meta-analysis). 21 trials were included in the evaluation: 16 used recombinant IFNagr; and 5 used lymphoblastoid IFNagr;. Results of the first meta-analysis indicated that IFNagr; was highly effective at inducing ALT normalisation lsqb;log-rank odds-ratio (95percnt; CI): 8.4 (6.3-11.2) at 24 weeks and 8.2 (6.2-10.9) at 48 weeksrsqb;. The pooled meta-analytical rate of ALT normalisation in the treatment group was 37percnt; at 24 weeks and 44percnt; at 48 weeks. Results of the second meta-analysis conducted in the subgroup of patients that achieved stable ALT normalisation following IFNagr; treatment revealed that remission was maintained after drug discontinuation in 47percnt; of patients (pooled meta-analytical rate after a follow-up period of 12 to 60 weeks). Relapsefree remission during the follow-up period was 59percnt; in patients treated with lymphoblastoid IFNagr; versus 43percnt; in patients treated with recombinant IFNagr;. Taking into consideration the results of both meta-analyses, the global rate of success, i.e. the probability of achieving remission with treatment and of maintaining remission after drug discontinuation, is 17.4percnt; at 24 weeks of IFNagr; therapy. If the studies are stratified according to the type of IFNagr; administered, the global rates of success are 16percnt; for recombinant IFNagr; and 25percnt; for lymphoblastoid IFNagr;.
展开▼
